It accepts no liability for any damages or losses, however, caused in connection with the use of, or on the reliance of its advisory or related services. INDmoney makes no warranties or representations, express or implied, on products and services offered through the platform. IN-DP-690-2022 Depository Participant ID: CDSL 12095500 | Trading and Clearing Member of NSE (90267, M70042) and BSE (6779)| AMFIRegistration No: ARN-254564| Registered Office - 616, 6th Floor Suncity Success Tower, Sector 65, Gurugram, Haryana-122005 | CIN U67100HR2021PTC098653 |Compliance officer: Ameya M.
Stock omer registration#
INZ000305337 | SEBI Depository Participant Registration No. INDmoney Private Limited is carrying out the business in respect to stock broking activities and also carries out the activities of depository participant SEBI Registration No. CA0744 dated March 3, 2021.įinzoomers also carries out various facilitation activities like acting as digital platform for selling fixed deposits, Opening of Savings Bank Account, Digital lending platform, foreign remittance services in respect to US Stocks trading via tie-ups with various Banks/NBFCs and facilitation of US Stocks trading through Stock Broker-Dealer like Drivewealth & Alpaca which are registered with USA Securities Exchange Commission. Finzoomers got registered with IRDAI as Corporate Agent (Composite) vide registration no. įinzoomers Services Private Limited (“Finzoomers”) carries out the business of referrer, intermediary, and facilitation, for varied financial services, including solicitation of insurance policies as a Corporate Agent(Composite). Gaurav Sharma, Email Compliance Officer: Mr. BASL Registration No: 1154 [Principal Officer details: Mr. INA100012190 and is in the services and/or products, related to all kind of financial/ financial technology services, by using technology or otherwise, including but not limited to wealth management, financial technologies, investment advisory services, financial advice, financial analytics, distribution services and financial information.įinzoom Investment Advisors Private Limited - Investment Advisory Unit (Separately Identifiable Unit) Organizationįinzoom Investment Advisors Private Limited - Investment Advisory Unit (Separately Identifiable Unit) : is the holding Company which is registered with Securities Exchange Board of India as an investment advisor under SEBI (Investment Advisors) Regulations, 2013 (“IA regulations”) vide registration no. One of these novel targets, GPR174, modulates a new cancer immunity axis recently discovered by Omeros, and the company is advancing GPR174-targeting antibodies and small-molecule inhibitors. Omeros' pipeline holds a diverse group of preclinical programs including a proprietary-asset-enabled antibody-generating technology and a proprietary GPCR platform through which it controls 54 GPCR drug targets and their corresponding compounds.
Stock omer Activator#
OMS906, Omeros' inhibitor of MASP-3, the key activator of the alternative pathway of complement, is in a Phase 1 clinical trial, and the company's PDE7 inhibitor program OMS527, targeting addiction and movement disorders, has successfully completed a Phase 1 trial. Narsoplimab is also in multiple late-stage clinical development programs focused on other complement-mediated disorders, including IgA nephropathy, atypical hemolytic uremic syndrome and COVID-19.
Stock omer license#
Omeros' lead MASP-2 inhibitor narsoplimab targets the lectin pathway of complement and is the subject of a biologics license application under priority review by FDA for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy. Its commercial product OMIDRIA® (phenylephrine and ketorolac intraocular solution) 1%/0.3% continues to gain market share in cataract surgery. Omeros is a commercial-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market and orphan indications targeting inflammation, complement-mediated diseases, disorders of the central nervous system and immune-related diseases, including cancers.
0 kommentar(er)
